Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: A randomized clinical trial.
coagulation
combined oral contraception
dienogest
estradiol valerate
thrombin generation
Journal
Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
09
06
2022
received:
11
04
2022
accepted:
03
07
2022
pubmed:
2
8
2022
medline:
4
10
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
Contraceptives containing ethinylestradiol (EE) induce changes in the coagulation system and are associated with a risk of venous thromboembolism. However, studies comparing the effects of combined oral contraceptives containing EE and low-potency estrogens (ie, estradiol [E We enrolled 59 healthy, 18- to 35-year-old, non-smoking women, of whom three discontinued. The participants were randomly allocated to 9 weeks of continuous treatment with EV 2 mg + DNG 2-3 mg (n = 20), EE 0.03 mg + DNG 2 mg (n = 20), or DNG 2 mg (n = 19). Blood samples were collected at baseline and after 9 weeks. We assessed coagulation in vitro by thrombin generation using the Calibrated Automated Thrombogram. Thrombin generation was evaluated by lag time, time to thrombin peak, thrombin peak, and endogenous thrombin potential in response to tissue factor (1 pm). In vivo coagulation assessment was based on levels of prothrombin fragment 1 + 2 (F1 + 2) (thrombin generation) and D-dimer (fibrin turnover). NCT02352090. Lag time and time to thrombin peak remained unaltered after exposure to EV + DNG, whereas EE + DNG shortened both lag time (mean percentage change -24%, 95% confidence interval [CI] -32% to -15%; p < 0.01) and time to thrombin peak (-26%, 95% CI -37% to -16%; p < 0.01). EV + DNG induced lower thrombin peak and endogenous thrombin potential than EE + DNG (peak; +45%, 95% CI 22%-67% vs +147%,95% CI 96%-198%; p < 0.01, and endogenous thrombin potential; +26%, 95% CI 15%-38% vs +64%, 95% CI 51%-76%; p < 0.01). Median F1 + 2 levels remained unchanged with EV + DNG (p = 0.22) but increased within normal ranges with EE + DNG (from 152 pmol/L, 95% CI 127-206] pmol/L to 194 pmol/L, 95% CI 149-250 pmol/L, p = 0.04). The within-group change in D-dimer levels was not significant in any of the groups. DNG alone did not affect these biomarkers. Both in vitro and in vivo thrombin generation was lower after exposure to EV + DNG compared with EE + DNG. The lower thrombin generation measures after treatment with EV + DNG indicate less enhancement of coagulation potential and suggest that EV may be favorable to EE as a component of combined oral contraceptives.
Identifiants
pubmed: 35909329
doi: 10.1111/aogs.14428
pmc: PMC9812067
doi:
Substances chimiques
Contraceptives, Oral, Combined
0
Estrogens
0
Progestins
0
Ethinyl Estradiol
423D2T571U
Estradiol
4TI98Z838E
Levonorgestrel
5W7SIA7YZW
Nandrolone
6PG9VR430D
Fibrin
9001-31-4
Thromboplastin
9035-58-9
Thrombin
EC 3.4.21.5
Banques de données
ClinicalTrials.gov
['NCT02352090']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1102-1111Informations de copyright
© 2022 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Références
Acta Obstet Gynecol Scand. 2022 Oct;101(10):1102-1111
pubmed: 35909329
Contraception. 2008 Nov;78(5):384-91
pubmed: 18929735
Contraception. 2016 Oct;94(4):328-39
pubmed: 27343748
Br J Haematol. 2007 Oct;139(2):289-96
pubmed: 17897305
Contraception. 2013 Jun;87(6):706-27
pubmed: 23375353
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3008-e3017
pubmed: 35279718
Horm Mol Biol Clin Investig. 2018 Nov 17;37(2):
pubmed: 30447140
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32303765
J Thromb Haemost. 2010 Aug;8(8):1736-44
pubmed: 20553380
Br J Haematol. 1997 Apr;97(1):233-8
pubmed: 9136971
Haemophilia. 2019 Mar;25(2):334-342
pubmed: 30715788
Br J Haematol. 2007 Sep;138(6):769-74
pubmed: 17760809
J Thromb Thrombolysis. 2016 Jan;41(1):3-14
pubmed: 26780736
Contraception. 2021 Jan;103(1):53-59
pubmed: 33098852
Thromb Res. 2010 Jul;126(1):5-11
pubmed: 20163835
Acta Obstet Gynecol Scand. 2002 Jun;81(6):482-90
pubmed: 12047300
Hematol Transfus Cell Ther. 2019 Jul - Sep;41(3):244-252
pubmed: 31085150
Am J Obstet Gynecol. 1982 Nov 1;144(5):511-8
pubmed: 6291391
Res Pract Thromb Haemost. 2019 Jul 18;3(4):758-768
pubmed: 31624796
Clin Drug Investig. 2011;31(8):573-584
pubmed: 21721593
Contraception. 2017 May;95(5):456-463
pubmed: 28088496
Thromb Haemost. 2007 Dec;98(6):1350-6
pubmed: 18064335
Contraception. 2003 Mar;67(3):173-85
pubmed: 12618251
Thromb Haemost. 2011 Nov;106(5):901-7
pubmed: 21947267
Lancet. 1994 Nov 26;344(8935):1453-7
pubmed: 7968118
J Thromb Haemost. 2013 May;11(5):855-61
pubmed: 23410231
Thromb Haemost. 2011 Mar;105(3):560-7
pubmed: 21225090
Cochrane Database Syst Rev. 2014 Mar 03;(3):CD010813
pubmed: 24590565
Eur J Contracept Reprod Health Care. 2021 Dec;26(6):439-446
pubmed: 34644228
BMJ. 2016 May 10;353:i2002
pubmed: 27164970
Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53
pubmed: 13679651
Drugs R D. 2011;11(2):159-70
pubmed: 21679006
Thromb Res. 2012 May;129(5):e257-62
pubmed: 22425318
Thromb Res. 2017 Sep;157:49-54
pubmed: 28692840
Eur J Contracept Reprod Health Care. 2011 Dec;16(6):444-57
pubmed: 22066891
Acta Obstet Gynecol Scand. 2022 Aug;101(8):846-855
pubmed: 35633036
J Thromb Haemost. 2008 Feb;6(2):346-51
pubmed: 18067603